Loading
Latest filing published 30 Sept 2022 for TFF Pharmaceuticals, Inc., €102k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Randy H. Thurman is a declared insider at 4 companies (board member); the most frequent names are TFF Pharmaceuticals, Inc., Presbia PLC and Outlook Therapeutics, Inc. Over a trading history stretching from 24 May 2016 to 29 September 2022, the count stands at 14 filings.
On the open market, the record shows 4 purchases worth €45k and 3 sales worth €713k. Sales outweigh purchases by €668k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 5 share grants and 2 option exercises. 2022 to date brings no purchases and 1 sale.
A typical purchase (the median) is worth €8,511. 2 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The record was last updated on 30 September 2022 with an open-market sale (€176k) in TFF Pharmaceuticals, Inc. The last insider purchase was made public on 19 May 2021, 1,984 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations